Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 9/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | BCL6 | P41182 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | STK17B | O94768 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13421119 | 0.93 | CSNK2A1 (0.45) | CSNK2A1CSNK2A2CSNK2BAURKAJAK2 | |
| SCHEMBL3448386 | 0.93 | CSNK2A1 (0.45) | CSNK2A1CSNK2A2CSNK2BAURKAJAK2 | |
| SCHEMBL3449089 | 0.88 | STK17A (0.44) | CSNK2A1AURKABCL6STK17ASTK17B | |
| SCHEMBL3451563 | 0.88 | CSNK2A1 (0.48) | CSNK2A1CSNK2A2CSNK2BAURKAJAK2 | |
| SCHEMBL13311591 | 0.86 | CSNK2A1 (0.47) | CSNK2A1CSNK2A2CSNK2BAURKAJAK2 | |
| SCHEMBL3450308 | 0.86 | STK17A (0.51) | CSNK2A1CSNK2A2CSNK2BAURKAJAK2 | |
| SCHEMBL3457207 | 0.86 | CSNK2A1 (0.48) | CSNK2A1CSNK2A2CSNK2BAURKAJAK2 | |
| SCHEMBL3448962 | 0.86 | STK17A (0.48) | CSNK2A1CSNK2A2CSNK2BAURKAJAK2 | |
| SCHEMBL13310846 | 0.85 | BCL6 (0.50) | CSNK2A1CSNK2A2CSNK2BBCL6STK17A | |
| SCHEMBL3448505 | 0.84 | CSNK2A1 (0.57) | CSNK2A1CSNK2A2CSNK2BAURKABCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | CSNK2A1 1858/4885CSNK2A2 1967/4885CSNK2B 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.